Pliant Therapeutics announces interim Phase 1 data from PLN-101095

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin alphavbeta8 and alphavbeta1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor -refractory advanced or metastatic solid tumors. Interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily dose, representing a 50% objective response rate at the highest dose tested to date. PLN-101095 was generally well tolerated across all doses tested. Nine patients with six different tumor types were enrolled in cohorts one through three of the trial. Patients were treated for 14 days with PLN-101095 at doses of 250 mg, 500 mg or 1000 mg administered orally BID, followed by treatment with a combination of PLN-101095 and pembrolizumab at 200 mg administered intravenously every three weeks. Scans were conducted at baseline, Day 14, Week 10, and every 8 weeks thereafter.